The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 01, 2022

Filed:

Sep. 19, 2017
Applicants:

Oncoc4, Inc., Rockville, MD (US);

Children's Research Institute, Children's National Medical Center, Washington, DC (US);

Inventors:

Yang Liu, Washington, DC (US);

Pan Zheng, Washington, DC (US);

Martin Devenport, Gaithersburg, MD (US);

Wei Wu, Washington, DC (US);

Xuexiang Du, Washington, DC (US);

Mingyue Liu, Washington, DC (US);

Fei Tang, Washington, DC (US);

Assignees:

ONCOC4, INC., Rockville, MD (US);

CHILDREN'S NATIONAL MEDICAL CENTER, Washington, DC (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); C07K 16/46 (2006.01); A61K 38/00 (2006.01); A61P 37/06 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); C07K 14/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70596 (2013.01); A61K 39/39541 (2013.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01); C07K 14/00 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 38/00 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01);
Abstract

This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.


Find Patent Forward Citations

Loading…